Finding needles in haystacks: Omass unveils pipeline aimed at tough-to-drug targets

November 2021

"Nov. 15, 2021

LONDON – There’s not yet proof of the pudding, but Omass Therapeutics Ltd.’s new structure-based technology has passed a key test, in enabling the discovery of orally available small molecules aimed at intractable and poorly drugged membrane and complex-bound protein targets. The targets, including G protein-coupled receptors (GPCRs), intracellular protein complexes and solute carriers, are relevant to immunology indications and rare diseases with high unmet need."

Read more at the source

#DrGPCR #GPCR #IndustryNews